MicroRNA-21 Acts As an Oncomir Through Multiple Targets in Human Hepatocellular Carcinoma
Overview
Authors
Affiliations
Background & Aims: MicroRNA-21 negatively regulates several targets, thereby affecting tumorigenesis. However, its mechanism of action in human hepatocellular carcinoma is poorly understood, and no direct evidence has shown a correlation between microRNA-21 function and phenotype. In this study, we investigate the function of microRNA-21 as a potent oncomir and probe the relationship between microRNA-21, its targets, and phenotypic alterations.
Methods: We designed a set of rescue experiments using different combinations of anti-microRNA-21, siRNA, and a negative control to modulate the protein level of microRNA-21 targets and resulting phenotypic alterations. MicroRNA-21 was suppressed using anti-microRNA-21 to further uncover its effect on several critical signaling pathways.
Results: We demonstrate that hepatocellular carcinoma is characterized by elevated levels of microRNA-21 and marked reductions of PTEN, PDCD4, and RECK expression. Silencing of PTEN and PDCD4 to prevent their induction by anti-microRNA-21 treatment led to decreased apoptosis and increased invasion, while silencing of RECK only led to increased invasion. Moreover, knockdown of microRNA-21 resulted in alterations of the Akt signaling pathway, the expression of p21 and MMP families, which are associated with apoptosis, and the cell cycle or invasiveness of cancer cells.
Conclusions: MicroRNA-21 simultaneously regulates multiple programs that enhance cell proliferation, apoptosis or tumor invasiveness by targeting PTEN, PDCD4, and RECK in hepatocellular carcinomas. Targeting of microRNA-21 is sufficient to limit tumor cell proliferation and invasion in a manner that is likely to involve associated changes in multiple targets, suggesting that suppression of microRNA-21 may be a novel approach for the treatment of hepatocellular carcinoma.
Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway.
Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J Front Cell Dev Biol. 2024; 12:1431423.
PMID: 39156976 PMC: 11327086. DOI: 10.3389/fcell.2024.1431423.
Tang X, Chen Y, Wang B, Luo D, Wang J, He Y ACS Nano. 2024; 18(21):13950-13965.
PMID: 38751197 PMC: 11140835. DOI: 10.1021/acsnano.4c04147.
Palladini G, Di Pasqua L, Croce A, Ferrigno A, Vairetti M Int J Mol Sci. 2023; 24(24).
PMID: 38139236 PMC: 10743940. DOI: 10.3390/ijms242417407.
Du Y, Zhou Y, Zheng X, Duan Y, Gu Z, Yin Y Aging (Albany NY). 2023; 15(14):7308-7323.
PMID: 37506248 PMC: 10415562. DOI: 10.18632/aging.204915.
Liu X, Yang S, Wang L, Wu X, Wang X, Ou C Theranostics. 2023; 13(9):2774-2786.
PMID: 37284454 PMC: 10240819. DOI: 10.7150/thno.81776.